基因指导下的抗凝治疗  

Genetic Polymorphisms and Anticoagulation Therapy with Individualizing

作　　者：吴岩峰[1] 丁红[1] 刘庆萍[1] 王辉[1] 

机构地区：[1]南京医科大学第二附属医院神经内科,南京210003

出　　处：《中国卒中杂志》2014年第4期303-308,共6页Chinese Journal of Stroke

摘　　要：抗凝治疗是急性冠状动脉综合征、心房颤动、静脉血栓形成、肺栓塞等栓塞类疾病非常有效的治疗手段。抗凝药物包括肝素、华法林、达比加群、利伐沙班、阿哌沙班等。抗凝药物剂量个体差异大、出血风险高。如何提高抗凝治疗的有效性和安全性作为目前的研究热点。基因多态性在抗凝药物的剂量效应关系方面起了非常重要的作用。本文旨在探讨影响华法林、达比加群等抗凝药物的遗传因素,为个体化治疗提供依据。Anticoagulation therapy is currently prescribed for treatment on thrombotic disorders, such as acute coronary syndromes, atrial fibrillation, vein thrombosis, pulmonary embolism. Currently, anticoagulants include heparin, warfarin, dabigatran, rivaroxaban, apixaban and so on. However, anticoagulants vary in dose on individual patient. One of the hot researches is how to increase the efifcacy and safety of anticoagulation. Genetic polymorphisms are thought to contribute to the wide intraindividual variability in anticoagulant drug response. Here, we review the genetic mechanisms contributing to the variability in response to warfarin and dabigatran, and propose the personal management of anticoagulation therapy.

关 键 词：抗凝治疗 华法林 达比加群 基因多态性 

分 类 号：R973.2[医药卫生—药品]